复星医药(02196.HK)24价肺炎球菌多糖结合疫苗于中国获批临床试验

阿斯达克财经
05 Mar

复星医药(02196.HK) 公布,旗下控股子公司复星安特金(成都)生物制药,于近日收到国家药监局关于24价肺炎球菌多糖结合疫苗的临床试验批准。复星安特金(成都)生物制药拟于条件具备后于中国境内开展该疫苗的I期临床试验。
据介绍,该疫苗为复星医药自主研发的预防用生物制品,拟用于预防由肺炎球菌血清型引起的感染性疾病。截至今年1月,复星医药现阶段针对该疫苗的累计研发投入约为4,400万元人民币。

另外,截至周二(4日),于全球范围内尚无24价肺炎球菌多糖结合疫苗获批上市。(js/k)
(港股报价延迟最少十五分钟。沽空资料截至 2025-03-04 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10